

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for ...


finnCap Interim Profit More Than Doubles; Chair To Step Down


(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respira...


Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients


UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study


Synairgen Raises GBP80 Million In Placing, To Launch Open Offer


IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial


Synairgen Progresses Covid-19 Treatment As Expenses Increase